Overview

Effects of Denosumab on the Pharmacokinetics of Etanercept

Status:
Terminated
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study was to characterize the effects of a single dose of denosumab on the pharmacokinetics (PK) of etanercept in postmenopausal women with low bone mineral density (BMD) and rheumatoid arthritis based on area under the serum concentration-time curve (AUC) and maximum observed serum concentration (Cmax).
Phase:
Phase 1
Details
Lead Sponsor:
Amgen
Treatments:
Denosumab
Etanercept